| No selection | Clinically guided strategy | Biologically guided strategy | |||
| Erlotinib | Erlotinib | Docetaxel | Erlotinib | Docetaxel | |
| Patients | 522 | 114 | 408 | 44 | 478 |
| Males | 354 (68) | 0 | 354 (87) | 27 (61) | 327 (68) |
| Median age yrs | 63 | 63 | 63 | 67 | 63 |
| Performance status | |||||
| 0–1 | 331 (65) | 79 (69) | 252 (69) | 29 (66) | 302 (69) |
| 2–3 | 146 (28) | 32 (28) | 114 (31) | 15 (34) | 135 (31) |
| Histology | |||||
| Squamous | 94 (18) | 0 | 94 (23) | 4 (9) | 90 (19) |
| Adenocarcinoma | 335 (65) | 114 (100) | 221 (55) | 32 (74) | 303 (64) |
| Other | 88 (17) | 0 | 88 (22) | 7 (16) | 81 (17) |
| Smoking status | |||||
| Current smoker | 75 (14) | 0 | 75 (19) | 4 (9) | 71 (15) |
| Former smoker | 349 (67) | 53 (47) | 296 (73) | 19 (43) | 330 (70) |
| Never-smoker | 94 (19) | 61 (53) | 33 (8) | 21 (48) | 73 (15) |
Data are presented as n or n (%).